Amicogen
아미코젠 · 092040
Consumer Staples Food & Beverage · KOSDAQ
Market cap US$76M (₩104.9B)
Overview
Amicogen makes specialist enzymes used in producing antibiotic ingredients, for example, the enzyme needed to manufacture the raw material at the heart of cephalosporin-class antibiotics, and has expanded into health-care ingredients such as collagen peptides and N-acetylglucosamine, as well as materials used in making antibody-based medicines.
Its customers include pharmaceutical manufacturers and biotech producers that rely on these inputs. Listed on KOSDAQ, Korea's tech and small-cap board, the company's business spans three areas: pharmaceutical enzymes, consumer health ingredients marketed under its own brand, and biopharmaceutical production materials.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue
- FY2023US$115.9M
- FY2024US$125.8M
- FY2025US$30.4M
Operating profit
- FY2023US$1.5M
- FY2024−US$5.1M
- FY2025−US$12.4M
Net income
- FY2023−US$15M
- FY2024−US$36.9M
- FY2025−US$22M
Key ratios (FY2025)
Why it matters
Amicogen collaborates with Liechtenstein-based Lysando on commercialising endolysin enzymes, a next-generation antibiotic class targeting drug-resistant bacteria.
Price charts coming soon
Interactive price history isn't here yet. Would you use it?